An alignment-independent three-dimensional quantitative structure-activity relationship study on ron receptor tyrosine kinase inhibitors

Recepteur d'Origine Nantais known as RON is a member of the receptor tyrosine kinase (RTK) superfamily which has recently gained increasing attention as cancer target for therapeutic intervention. The aim of this work was to perform an alignment-independent three-dimensional quantitative structure-activity relationship (3D QSAR) study for a series of RON inhibitors. A 3D QSAR model based on GRid-INdependent Descriptors (GRIND) methodology was generated using a set of 19 compounds with RON inhibitory activities. The generated 3D QSAR model revealed the main structural features important in the potency of RON inhibitors. The results obtained from the presented study can be used in lead optimization projects for designing of novel compounds where inhibition of RON is needed.

[1]  Alexandre Varnek,et al.  Comprehensive Analysis of Applicability Domains of QSPR Models for Chemical Reactions , 2020, International journal of molecular sciences.

[2]  Yuting Zhou,et al.  Identification of novel quinoline analogues bearing thiazolidinones as potent kinase inhibitors for the treatment of colorectal cancer. , 2020, European journal of medicinal chemistry.

[3]  Tianhao Weng,et al.  Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy , 2019, Journal of Immunotherapy for Cancer.

[4]  Shourong Liu,et al.  Design, synthesis, and biological evaluation of novel 3‐(thiophen‐2‐ylthio)pyridine derivatives as potential multitarget anticancer agents , 2019, Archiv der Pharmazie.

[5]  Jun Yu Li,et al.  Discovery of N1-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment. , 2019, European journal of medicinal chemistry.

[6]  R. Paulson,et al.  Neuroprotective Role of the Ron Receptor Tyrosine Kinase Underlying Central Nervous System Inflammation in Health and Disease , 2018, Front. Immunol..

[7]  Yuting Zhou,et al.  Identification of novel N1-(2-aryl-1, 3-thiazolidin-4-one)-N3-aryl ureas showing potent multi-tyrosine kinase inhibitory activities. , 2018, European journal of medicinal chemistry.

[8]  Danishuddin,et al.  Descriptors and their selection methods in QSAR analysis: paradigm for drug design. , 2016, Drug discovery today.

[9]  Dan A. Buzatu,et al.  Alignment-independent technique for 3D QSAR analysis , 2016, Journal of Computer-Aided Molecular Design.

[10]  Eric Therrien,et al.  Design, synthesis and RON receptor tyrosine kinase inhibitory activity of new head groups analogs of LCRF-0004. , 2015, Bioorganic & medicinal chemistry letters.

[11]  Eric Therrien,et al.  Design and synthesis of constrained analogs of LCRF-0004 as potent RON tyrosine kinase inhibitors. , 2015, Bioorganic & medicinal chemistry letters.

[12]  Eric Therrien,et al.  Design and synthesis of close analogs of LCRF-0004, a potent and selective RON receptor tyrosine kinase inhibitor. , 2015, Bioorganic & medicinal chemistry letters.

[13]  J. Freeman,et al.  Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets , 2015, Oncotarget.

[14]  Yi-Zeng Liang,et al.  A Combinational Strategy of Model Disturbance and Outlier Comparison to Define Applicability Domain in Quantitative Structural Activity Relationship , 2014, Molecular informatics.

[15]  Stefano Alcaro,et al.  Molecular interaction fields in drug discovery: recent advances and future perspectives , 2013 .

[16]  Ruiwen Zhang,et al.  MSP–RON signalling in cancer: pathogenesis and therapeutic potential , 2013, Nature Reviews Cancer.

[17]  S. Waltz,et al.  Ron receptor tyrosine kinase signaling as a therapeutic target , 2012, Expert opinion on therapeutic targets.

[18]  K. Rex,et al.  Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives. , 2012, Journal of medicinal chemistry.

[19]  Ruiwen Zhang,et al.  The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells , 2011, Molecular Cancer.

[20]  Jitender Verma,et al.  3D-QSAR in drug design--a review. , 2010, Current topics in medicinal chemistry.

[21]  Manuel Pastor,et al.  Development and Validation of AMANDA, a New Algorithm for Selecting Highly Relevant Regions in Molecular Interaction Fields , 2008, J. Chem. Inf. Model..

[22]  Guang-Fu Yang,et al.  Development of quantitative structure-activity relationships and its application in rational drug design. , 2006, Current pharmaceutical design.

[23]  Nina Nikolova-Jeliazkova,et al.  QSAR Applicability Domain Estimation by Projection of the Training Set in Descriptor Space: A Review , 2005, Alternatives to laboratory animals : ATLA.

[24]  Scott D. Kahn,et al.  Current Status of Methods for Defining the Applicability Domain of (Quantitative) Structure-Activity Relationships , 2005, Alternatives to laboratory animals : ATLA.

[25]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[26]  S. Pickett,et al.  GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. , 2000, Journal of medicinal chemistry.

[27]  M. H. Wang,et al.  Requirement of both tyrosine residues 1330 and 1337 in the C-terminal tail of the RON receptor tyrosine kinase for epithelial cell scattering and migration. , 2000, Biochemical and biophysical research communications.

[28]  G. Mayrhofer,et al.  Deregulated inflammatory response in mice lacking the STK/RON receptor tyrosine kinase. , 1997, Genes and function.

[29]  L. Naldini,et al.  RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. , 1994, The EMBO journal.

[30]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.